Immunocore Holdings (IMCR) has released an update.
On January 29, 2024, the Company announced a private offering of $300 million of convertible senior notes due 2030, with an option for initial purchasers to buy an additional $45 million of notes. The proceeds are intended for accelerating the clinical pipeline, commercial expansion, repaying existing loans, and other corporate purposes. The offering details are in a confidential memorandum, and the securities are not registered under the Securities Act or state laws, being available only to qualified institutional buyers.
For further insights into IMCR stock, check out TipRanks’ Stock Analysis page.
